• Price (EUR)41.60
  • Today's Change0.20 / 0.48%
  • Shares traded0.00
  • 1 Year change-26.37%
  • Beta--
Data delayed at least 15 minutes, as of Mar 20 2023.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The prescription drug business is engaged in the development of eight new drugs including hypercholesterolemia treatment drugs Crestor, antihypertensive drugs Ilbetan Family (Irbetan, Aimix, Iltra) and antidepressant drugs Sinbalta. The Company is engaged in the provision of information to contribute to medical care by maximizing its products. The over-the-counter (OTC) pharmaceutical business handles products tailored to customers' lifestyles. The in-vitro diagnostics business is engaged in the sale of products, as well as the provision of information on infectious diseases, cardiovascular diseases and allergic diseases. The Company mainly provides its products and services in Japan, Europe and North America markets.

  • Revenue in JPY (TTM)453.86bn
  • Net income in JPY200.91bn
  • Incorporated1919
  • Employees5.69k
  • Location
    Shionogi & Co Ltd3-1-8, Dosho-machi, Chuo-kuOSAKA-SHI 541-0045JapanJPN
  • Phone+81 662022161
  • Fax+81 662299596
  • Websitehttps://www.shionogi.co.jp/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.